Logo

PETVW

PetVivo Holdings, Inc.

PETVW

PetVivo Holdings, Inc. • NASDAQ
$0.03 ▲ 25.57% (+0.01)
Market Cap $656666
52w High $0.03
52w Low $0.03
Dividend Yield 0%
P/E -0.06
Volume 10.00K
Outstanding Shares 23.88M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $303.284K ▲ $2.285M ▲ $-3.008M ▼ -991.747% ▼ $-0.11 ▼ $-1.926M ▲
Q1-2026 $297.5K ▲ $2.031M ▼ $-2.311M ▲ -776.819% ▲ $-0.096 ▲ $-2.056M ▼
Q4-2025 $224.75K ▼ $2.263M ▼ $-2.42M ▼ -1.077K% ▼ $-0.12 ▼ $-1.835M ▼
Q3-2025 $583.313K ▲ $2.28M ▼ $-1.757M ▲ -301.217% ▲ $-0.085 ▲ $-1.701M ▲
Q2-2025 $200.72K $2.353M $-2.175M -1.084K% $-0.11 $-2.14M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2026 $767.914K ▼ $5.258M ▼ $1.075M ▼ $4.183M ▲
Q1-2026 $3.454M ▲ $6.89M ▼ $3.16M ▼ $3.731M ▼
Q4-2025 $377.689K ▲ $9.339M ▲ $5.12M ▲ $4.219M ▲
Q3-2025 $28.891K ▼ $3.112M ▼ $3.807M ▲ $-694.781K ▼
Q2-2025 $126.239K $3.187M $2.778M $409.171K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2026 $-3.008M ▼ $-2.194M ▼ $6.605K ▲ $-348.081K ▼ $-2.536M ▼ $-2.194M ▼
Q1-2026 $-2.311M ▲ $-1.634M ▼ $0 ▲ $4.71M ▲ $3.076M ▲ $-1.634M ▲
Q4-2025 $-2.42M ▼ $-1.23M ▼ $-521.204K ▼ $1.95M ▲ $198.798K ▲ $-1.751M ▼
Q3-2025 $-1.757M ▲ $-961.216K ▲ $-23.632K ▼ $887.5K ▼ $-97.348K ▼ $-984.848K ▲
Q2-2025 $-2.175M $-1.6M $-3.42K $1.718M $113.825K $-1.585M

Revenue by Products

Product Q2-2025Q3-2025Q4-2025Q1-2026
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement PetVivo looks like a very early-stage, essentially pre‑revenue company. Over the past several years it has not generated meaningful sales, while consistently recording operating losses. The loss levels are modest in absolute size but persistent, and the earnings per share have stayed negative, showing ongoing dilution of value per share rather than improvement in profitability. Overall, the business is still in the “build and invest” phase, not yet in a phase where its products are clearly paying for its operating structure.

Balance Sheet

Balance Sheet The balance sheet appears very thin, with only a small base of assets, limited cash, and no recorded debt. That absence of debt reduces financial strain from interest payments, but the small equity base and minimal resources suggest a fragile financial position that depends heavily on external financing and successful commercialization. There is little cushion if things take longer or cost more than planned.

Cash Flow

Cash Flow Cash flows show a straightforward story: the company is using cash in its operations and not yet generating cash from its products. Free cash flow is negative and there is no visible investment in large physical assets, which fits a model focused on research, product development, and commercialization efforts rather than heavy manufacturing. This pattern is typical for a small medical device innovator, but it also means ongoing funding needs until the business starts to scale revenue.

Competitive Edge

Competitive Edge Competitively, PetVivo is trying to carve out a niche in animal health, focused on joint and mobility issues in pets and horses. Its main product, Spryng, is positioned as a mechanical, cartilage‑mimicking treatment rather than a traditional drug, which sets it apart from pain medications and some biologics. The company backs this with a sizable patent portfolio and targets an underserved problem—painful osteoarthritis in aging pets. However, it competes in a market dominated by much larger animal health companies, so its success will depend on convincing veterinarians to adopt its products, building distribution, and sustaining its first‑mover edge in this niche category.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of PetVivo’s strategy. Its biomaterial platform and Spryng technology aim to address the underlying joint problem rather than just masking pain. It has also developed a ready‑to‑use PRP product and is experimenting with an AI platform, PetVivo.ai, to help veterinary clinics attract clients, which is a distinctive move beyond pure devices. Management has signaled a sizable pipeline across new animal indications, conditions like urinary incontinence, and even potential human applications. This breadth offers considerable upside potential if even a few programs work, but it also adds execution risk and complexity for a small company.

Summary

Overall, PetVivo is a very early‑stage, pre‑revenue medical device and services company in the animal health space. Financially, it is still loss‑making, with a light balance sheet and negative cash flow that point to continued dependence on outside capital. Strategically, it is trying to build a differentiated position through a patented biomaterial platform, niche focus on osteoarthritis and related conditions, and a new AI‑driven SaaS offering for veterinarians. The story is largely about future potential—successful product uptake, scaling of its AI platform, and progress on the pipeline—rather than current financial strength, and outcomes remain uncertain given the company’s small scale and ambitious agenda.